Ardsley Advisory Partners’s Audentes Therapeutics, Inc BOLD Stock Holding History

Ardsley Advisory Partners’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-10,072	Closed	-$302K	–	195
2018 Q1	$302K	Sell	10,072 -5,000	-33%	-$169K	0.05%	126
2017 Q4	$471K	Sell	15,072 -10,000	-40%	-$275K	0.06%	94
2017 Q3	$702K	Buy	25,072 +5,000	+25%	+$109K	0.09%	84
2017 Q2	$384K	Buy	20,072 +7,500	+60%	+$120K	0.06%	105
2017 Q1	$214K	Buy	+12,572	New	+$203K	0.03%	134

Other funds holding BOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Ardsley Advisory Partners's BOLD Position: Q2 2018 in Review

Ardsley Advisory Partners sold out of Audentes Therapeutics, Inc (BOLD) in Q2 2018, closing a stake of 10,072 shares — an estimated $302K sold.

Ardsley Advisory Partners first reported a position in BOLD in Q1 2017 and held it in 5 quarters. The position peaked at $702K in Q3 2017. 123 funds tracked by Wall St. Rank hold BOLD as of Q2 2018.

Ardsley Advisory Partners reported no remaining Audentes Therapeutics, Inc position as of Q2 2018 after selling out during the quarter.
Ardsley Advisory Partners sold 10,072 Audentes Therapeutics, Inc shares in Q2 2018, an estimated $302K.
Ardsley Advisory Partners first reported a position in Audentes Therapeutics, Inc in Q1 2017 and held it in 5 quarters.
Ardsley Advisory Partners's Audentes Therapeutics, Inc position peaked at $702K in Q3 2017.
123 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q2 2018.

Based on Ardsley Advisory Partners's 13F filing for Q2 2018, filed 14 Aug 2018.